The design, synthesis and evaluation of 24 isoindolinones as potential inhibitors of the MDM2-p53 interaction is described. The most potent inhibitor NU8231 (ELISA: IC 50 = 5.3 ± 0.9 µM) displays cellular activity in human SJSA cells. 
p53 is maintained by this negative feedback loop. 3, 4 The X-ray crystal structure of MDM2 bound to a p53 peptide corresponding to the transactivation loop, reveals a hydrophobic pocket on the surface of MDM2, into which the Phe19, Trp23, and Leu26 residues of p53 bind. 5 Inactivation of p53 through mutation is frequently found in a wide range of common sporadic cancers. However, around 7% of human tumours show evidence of amplification and overexpression of the MDM2 gene resulting in suppression of functional p53, promoting transformation and uncontrolled tumour growth. 6 Inhibitors of the MDM2-p53 binding interaction would be expected to restore normal p53 activity in MDM2 overexpressing cells and thus exert an anti-tumour effect. 7 A number of inhibitors of the MDM2-p53 interaction have been reported including potent peptide inhibitors, 8 the natural product chlorofusin, 9 and small molecules including the recently described 'nutlins'. 10, 11 Here we describe inhibitors of the MDM2-p53 interaction, based on an isoindolinone scaffold.
Preliminary screening studies, using an in vitro p53-MDM2 binding assay, identified compounds 1a and Using the published structure of the MDM2-p53 binding site, 5 we have employed computational methods, and focussed library synthesis based on the isoindolinone template, to develop compounds with improved inhibitory activity. These studies have resulted in the identification of a number of inhibitors (Table 1) with increased potency over the preliminary compounds (1a and 2a,b).
Briefly, the determination of single, low-energy binding modes for 1a and 2b was attempted by docking the compounds into the published crystal structure of MDM2 (1YCR) 5 using easyDock. 13 A single plausible binding mode was chosen for each compound, and the position of the isoindolinone scaffold was preserved during the following virtual screen of new substituents. The binding interaction between ligand and receptor was explored using a simulated annealing optimisation of an empirical freeenergy function using the program Skelgen. 14 Reagents able to form at least one additional H-bond with target residues of MDM2 were selected as 'virtual hits' and suggested for synthesis, a selection of which were synthesised. Comparison of the inhibitory activity of these synthesised 'virtual hits' with a set of isoindolinones bearing randomly selected substituents revealed no significant difference in activity between the two sets (data not shown).
At this point, the binding mode determination was revisited with the six most active compounds synthesised ( Table 1 ). The six lead compounds were docked into the MDM2 crystal structure 1YCR, using the programs easyDock 13 and GOLD. 15 It was impossible to distinguish a single preferred binding mode from the large pool of docking solutions. Previously, it has been shown that the probability of predicting the experimental binding mode correctly increases significantly when multiple binding modes are considered. 16 Therefore, a total of 24 (6 per compound x 2 per stereoisomer x 2 per docking program) high scoring, unique binding modes were selected as starting points for a second round of virtual screening. Again, reagents able to form additional hydrogen bonds with the protein were suggested for synthesis. In order to validate this approach 57 hit compounds were selected, including substituents unique to each binding mode. The majority of these compounds were synthesised and assayed for inhibition of MDM2-p53 binding using the ELISA format assay. A number of compounds that displayed improved activity were identified including 2e, 2f and 2g ( Table 2) . The percentage MDM2 inhibition at a given concentration is calculated as the (RLU detected in the compound treated sample ÷ RLU of DMSO controls) x 100. The IC 50 was calculated using a plot of % MDM2 inhibition vs concentration and is the average of three independent experiments. The results are presented in Table 2 .
In comparison with the lead compounds bearing an unsubstituted phenyl group at the C3 position (2d,e and g), none of the newly synthesised compounds displayed improved potency, with only the syringic alcohol derivative 2k and the 2-(2-pyridyl)ethoxy derivative 2m showing inhibition comparable with the 4-t-butylbenzyloxy derivative 2d. In the 3-(4-chlorophenyl) series, the N-propyl substituted 3-hydroxypropoxy derivative 2r was equipotent with the lead N-benzyl compound 2c. In contrast, the Npropyl substituted 2-(2-pyridyl)ethoxy derivative 2s was significantly less potent than the lead N-benzyl compound 2f. The reverse trend was observed for the N-propyl syringic alcohol derivative 2q, which was significantly more potent than the N-propyl derivative 2o. Interestingly, for the syringic alcohol derivatives, the 4-chloro substituent was favourable in the N-propyl series (2k and q) but resulted in a loss of potency in the N-benzyl series (2i and q). In the N-ethylacetamido series, the 3-(4-chlorophenyl)
derivatives (2v and w) were significantly less potent than the lead 2g. In the light of these disappointing results, and the difficulties encounted with the synthesis of these derivatives, this series was abandoned.
Similarly, in the 4-(2-trimethylsilylethoxy)methoxyphenyl series, none of the compounds synthesised (2v-z) displayed improved potency compared with the lead 1b and the series was not completed.
The increased potency observed for the 4-chlorophenyl compound 2q, is consistent with the predicted binding mode for the parent 2g, which is seen bound to MDM2 with the phenyl ring occupying the tryptophan binding pocket, the N-propylisoindolinone in contact with a broad, shallow, hydrophobic cleft, and the phenolic OH of the syringic alcohol making an H-bond to the backbone of Tyr100 on MDM2 
